Gene therapy of cardiovascular diseases
Komitet Biotechnologii PAN ; Instytut Chemii Bioorganicznej PAN
Despite progress in pharmacotherapy, there is still a lack of efficient treatment of advanced stages of cardiovascular diseases. Therefore, great expectations are connected with gene therapy. First clinical experiments of gene transfer of vascular endothelial growth factor (VEGF) were carried out in 1994-1998 on patients with critical leg ischemia. They resulted in the improvement of vascularisation and prevented the amputation of the limbs. Promising results have been also obtained with DNA decoys binding the EF2 transcription factor. In this way, the expression of genes enhancing the proliferation of vascular smooth muscle cells have been inhibited and in consequence the narrowing of the lumen of arterio-venous bypasses have been inhibited.
Biotechnologia, vol.66, 3 (2004)-.
0860-7796 ; oai:rcin.org.pl:113846
Biblioteka Instytutu Chemii Bioorganicznej PAN
Licencja Creative Commons Uznanie autorstwa-Na tych samych warunkach 4.0
Instytut Chemii Bioorganicznej Polskiej Akademii Nauk
Instytut Chemii Bioorganicznej Polskiej Akademii Nauk
2 paź 2020
18 lut 2020
195
https://rcin.org.pl/ichb/publication/142172
Nazwa wydania | Data |
---|---|
Terapia genowa chorób układu krążenia | 2 paź 2020 |
Józkowicz, Alicja Dulak, Józef
Tyczewska, Agata Bąkowska- Żywicka, Kamila
Pieczyński, Marcin Bielewicz, Dawid Dolata, Jakub Szweykowska-Kulińska, Zofia